Clinical Trial: Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299292) titled 'Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)' on Dec. 09.

Brief Summary: Hypothesis

The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in >=80-90% of cases.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Prostate Cancer (Diagnosis)

Intervention: DRUG: Abiraterone 250 mg with food + prednisone

Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testos...